GlassScriptPhysician profile
Neera Grover
NPI 1023169489
$2,396.91
in general payments reported to CMS, 2019-2025
29 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $67.05 · 2021: $341 · 2022: $270 · 2023: $167 · 2024: $626 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209 · Gift: $164 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.48 |
| Gift | $163.62 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $329.86 | 2021-2024 | Dificid |
| Braintree Laboratories, INC. | $315.79 | 2019-2024 | Sutab, Suflave |
| Janssen Biotech, INC. | $280.43 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $276.10 | 2020-2025 | |
| Gilead Sciences, INC. | $247.92 | 2019-2025 | |
| Madrigal Pharmaceuticals | $221.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $130.64 | 2019-2025 | |
| Genzyme Corporation | $110.05 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $85.59 | 2024-2025 | Zenpep |
| Redhill Biopharma INC. | $83.37 | 2022-2024 | Talicia |
| Novo Nordisk INC | $57.59 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $46.08 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.01 | 2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.22 | 2021 | |
| Nestle Healthcare Nutrition INC. | $24.33 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Albireo Pharma, INC. | $23.39 | 2024 | Iqirvo |
| Tela Bio, INC. | $22.05 | 2019 | |
| Ardelyx, INC. | $21.71 | 2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $20.87 | 2022 | |
| Exact Sciences Corporation | $16.31 | 2024 | Cologuard Collection Kit |
| Kci USA, INC. | $15.74 | 2019 | |
| Trevena, INC. | $12.05 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neera Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.